103 related articles for article (PubMed ID: 2212539)
1. The susceptibility of Campylobacter pylori to antiulcer agents and antibiotics.
Nagate T; Numata K; Hanada K; Kondo I
J Clin Gastroenterol; 1990; 12 Suppl 1():S135-8. PubMed ID: 2212539
[TBL] [Abstract][Full Text] [Related]
2. Effects of anti-ulcer agents on antibiotic activity against Helicobacter pylori.
Sunairi M; Watanabe K; Suzuki T; Tanaka N; Kuwayama H; Nakajima M
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S121-4. PubMed ID: 7735928
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori.
Koga T; Kawada H; Utsui Y; Domon H; Ishii C; Yasuda H
J Antimicrob Chemother; 1996 May; 37(5):919-29. PubMed ID: 8737142
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents.
Glupczynski Y; Delmee M; Bruck C; Labbe M; Avesani V; Burette A
Eur J Epidemiol; 1988 Jun; 4(2):154-7. PubMed ID: 3402574
[TBL] [Abstract][Full Text] [Related]
5. [In vitro anti-microbial activity against H. pylori and clinical efficacy of various drugs].
Fujioka T; Kawasaki H; Su WW; Nasu M
Nihon Rinsho; 1993 Dec; 51(12):3255-60. PubMed ID: 8283643
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori.
Shibata K; Kasuga O; Yasoshima A; Matsushita T; Kawakami Y
Jpn J Antibiot; 1997 Jun; 50(6):525-31. PubMed ID: 9258741
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria.
Ani AE; Malu AO; Onah JA; Queiroz DM; Kirschner G; Rocha GA
Trans R Soc Trop Med Hyg; 1999; 93(6):659-61. PubMed ID: 10717760
[TBL] [Abstract][Full Text] [Related]
8. Sofalcone for treatment of Helicobacter pylori infection.
Fujioka T; Murakami K; Kubota T; Kodama R; Honda S; Nasu M
J Gastroenterol; 1996 Nov; 31 Suppl 9():56-8. PubMed ID: 8959521
[TBL] [Abstract][Full Text] [Related]
9. Sucralfate affects the susceptibility of Helicobacter pylori to antimicrobial agents.
Slomiany BL; Piotrowski J; Majka J; Slomiany A
Scand J Gastroenterol Suppl; 1995; 210():82-4. PubMed ID: 8578215
[TBL] [Abstract][Full Text] [Related]
10. Effect of sofalcone on adherence, production of vacuolating toxin, and induction of interleukin-8 secretion by Helicobacter pylori.
Kamiya S; Osaki T; Kumada J; Yamaguchi H; Taguchi H
J Clin Gastroenterol; 1997; 25 Suppl 1():S172-8. PubMed ID: 9479645
[TBL] [Abstract][Full Text] [Related]
11. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.
Malanoski GJ; Eliopoulos GM; Ferraro MJ; Moellering RC
Eur J Clin Microbiol Infect Dis; 1993 Feb; 12(2):131-3. PubMed ID: 8388791
[TBL] [Abstract][Full Text] [Related]
12. [Sofalcone].
Fukuda Y; Shimoyama T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():704-9. PubMed ID: 11979875
[No Abstract] [Full Text] [Related]
13. Combination therapy with clarithromycin and sofalcone for eradication of Helicobacter pylori.
Kodama R; Fujioka T; Fujiyama K; Kawasaki H; Kubota T; Nasu M
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S125-8. PubMed ID: 7735929
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.
Sjöström JE; Larsson H
J Med Microbiol; 1996 Jun; 44(6):425-33. PubMed ID: 8636959
[TBL] [Abstract][Full Text] [Related]
15. Activities of beta-lactams and macrolides against Helicobacter pylori.
Hassan IJ; Stark RM; Greenman J; Millar MR
Antimicrob Agents Chemother; 1999 Jun; 43(6):1387-92. PubMed ID: 10348758
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of sofalcone on tumor necrosis factor-alpha and interleukin-1 beta production in human monocytes stimulated by Helicobacter pylori water extract.
Fujiwara Y; Higuchi K; Fukuda T; Watanabe T; Tominaga K; Arakawa T
Drugs Exp Clin Res; 2001; 27(3):103-6. PubMed ID: 11447767
[TBL] [Abstract][Full Text] [Related]
17. The effect of sofalcone on indomethacin-induced gastric ulcers in a Helicobacter pylori-infected gnotobiotic murine model.
Kabir AM; Shimizu K; Aiba Y; Igarashi M; Takagi A; Koga Y
Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():223-9. PubMed ID: 10807428
[TBL] [Abstract][Full Text] [Related]
18. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.
Isomoto H; Furusu H; Ohnita K; Wen CY; Inoue K; Kohno S
World J Gastroenterol; 2005 Mar; 11(11):1629-33. PubMed ID: 15786539
[TBL] [Abstract][Full Text] [Related]
19. A novel in vitro effect of the mucosal protective agent sofalcone--inhibition of chemotactic motility in Helicobacter pylori.
Yoshiyama H; Nakamura H; Okamoto T; Okita K; Nakazawa T
Aliment Pharmacol Ther; 2000 Apr; 14 Suppl 1():230-6. PubMed ID: 10807429
[TBL] [Abstract][Full Text] [Related]
20. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.
Loo VG; Fallone CA; De Souza E; Lavallée J; Barkun AN
J Antimicrob Chemother; 1997 Dec; 40(6):881-3. PubMed ID: 9462442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
